<DOC>
	<DOCNO>NCT00605852</DOCNO>
	<brief_summary>This study design assess safety tolerability single , escalate oral dos repeat oral dos ( 7 day , daily ) GSK835726 healthy male subject</brief_summary>
	<brief_title>Investigation Of New Oral Anti-Histamine Healthy Male Subjects</brief_title>
	<detailed_description>A double-blind , placebo control , randomize cross-over single dose escalation study double-blind , placebo control , randomise parallel group 7-days daily repeat dose study investigate safety , tolerability , pharmacokinetics pharmacodynamics oral H1/H3 dual antagonist compound healthy male subject</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Inclusion criterion : Male age 18 50 year inclusive . Body mass index within range 1929kg/m2 ( inclusive ) , weight range 55kg100kg ( inclusive ) . Healthy ( defined individual free significant nasal , cardiac , pulmonary , gastrointestinal , hepatic , renal , haematological , malignancy , endocrine , neurological psychiatric disease determine history , physical examination screen investigation ) . Nonsmoking status verify urinary cotinine level 300 ng/mL cotinine screen visit . This include exsmokers give smoke &gt; 1 year . Subjects enter cohort I III : Skin prick test reactivity histamine 3mm wheal &gt; saline control associate surround erythema . Subjects enter cohort I III : Negative skin prick test reactivity saline control . The subject able willing give write informed consent take part study available complete study measurement . If sexually active , male subject must agree use condom spermicide sexual intercourse , first dose study drug 84 day last dose . In addition , female partner male subject , childbearing potential , must use reliable contraceptive method must refrain sexual intercourse first dose study medication 84 day last dose . Reliable form contraception include IUD , condom diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant , contraceptive patch tubal ligation . '' Exclusion criterion : As result medical interview , physical examination screen investigation , Investigator appropriately qualify designee considers subject unfit study . The subject history drug allergy , , opinion Investigator appropriately qualify designee , contraindicate participation , include know suspected personal history family history adverse reaction hypersensitivity anti histamine . The subject participate study new molecular entity previous 3 month study previous 2 month . The subject regularly , average , drink 21 unit alcohol week average intake 3 unit per day ( One unit = 125ml wine 25ml spirit 250ml normal strength lager ) . The subject currently take regular ( course ) medication , prescribe ( include antiallergy medication ) ( include counter medication herbal remedy St Johns Wort ) . Paracetamol exception permit daily dos 4g follow dos investigational product . The subject test positive hepatitis C antibody hepatitis B surface antigen . The subject test positive HIV . The subject positive drug abuse alcohol test . Donation blood ( 450 mL ) within 2 month screen . Donation study would result &gt; 500mL blood donate 56 day period Significant cardiac conduction abnormality two ECG tracing separate least 5 minute screen , include : QTc interval &gt; 450 msec PR interval &gt; 240 msec Evidence second third degree atrioventricular ( AV ) block Ventricular rate &lt; 45 beat per minute ( bpm ) &gt; 100 bpm Pathological Qwaves ( define Qwave &gt; 40 msec depth great 0.40.5 mV ) Evidence ventricular preexcitation Evidence leave axis deviation , nonspecific intraventricular conduction delay ( QRS duration &gt; 120 msec ) , complete leave bundle branch block Subjects Perennial Allergic Rhinitis ( PAR ) Seasonal Allergic Rhinitis ( SAR ) , unless subject SAR asymptomatic outside pollen season Subjects dermatographism skin condition might interfere wheal flare test . Subjects unable comply study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>first time human</keyword>
</DOC>